260 related articles for article (PubMed ID: 28114941)
1. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
Pardo-Marín L; Martínez-Subiela S; Pastor J; Tvarijonaviciute A; Garcia-Martinez JD; Segarra S; Cerón JJ
BMC Vet Res; 2017 Jan; 13(1):31. PubMed ID: 28114941
[TBL] [Abstract][Full Text] [Related]
2. Renal dialysis and long-term treatment of a dog with kidney disease associated with canine leishmaniosis.
Baneth G; Segev G; Mazaki-Tovi M; Chen H; Kuzi S
Parasit Vectors; 2018 Mar; 11(1):151. PubMed ID: 29554974
[TBL] [Abstract][Full Text] [Related]
3. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study.
Pierantozzi M; Roura X; Paltrinieri S; Poggi M; Zatelli A
J Am Anim Hosp Assoc; 2013; 49(4):231-6. PubMed ID: 23690493
[TBL] [Abstract][Full Text] [Related]
4. Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis.
Daza González MA; Miró G; Fermín Rodríguez M; Rupérez Noguer C; Fragío Arnold C
Res Vet Sci; 2019 Oct; 126():131-138. PubMed ID: 31491669
[TBL] [Abstract][Full Text] [Related]
5. Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
Paradies P; Sasanelli M; Amato ME; Greco B; De Palo P; Lubas G
Res Vet Sci; 2012 Oct; 93(2):843-7. PubMed ID: 22296941
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
8. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
[No Abstract] [Full Text] [Related]
9. Assessment of acute kidney injury in canine parvovirus infection: Comparison of kidney injury biomarkers with routine renal functional parameters.
van den Berg MF; Schoeman JP; Defauw P; Whitehead Z; Breemersch A; Goethals K; Daminet S; Meyer E
Vet J; 2018 Dec; 242():8-14. PubMed ID: 30503549
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of acute kidney injury in dogs with complicated or uncomplicated Babesia rossi infection.
Defauw P; Schoeman JP; Leisewitz AL; Goddard A; Duchateau L; Aresu L; Meyer E; Daminet S
Ticks Tick Borne Dis; 2020 May; 11(3):101406. PubMed ID: 32107174
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment.
Cantos-Barreda A; Escribano D; Martínez-Subiela S; Pardo-Marín L; Segarra S; Cerón JJ
Vet Immunol Immunopathol; 2018 Apr; 198():65-69. PubMed ID: 29571520
[TBL] [Abstract][Full Text] [Related]
12. TLR-2 and TLR-4 transcriptions in unstimulated blood from dogs with leishmaniosis due to Leishmania infantum at the time of diagnosis and during follow-up treatment.
Montserrat-Sangrà S; Alborch L; Ordeix L; Solano-Gallego L
Vet Parasitol; 2016 Sep; 228():172-179. PubMed ID: 27692322
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis.
Martinez-Subiela S; Horvatic A; Escribano D; Pardo-Marin L; Kocaturk M; Mrljak V; Burchmore R; Ceron JJ; Yilmaz Z
Vet Immunol Immunopathol; 2017 Sep; 191():60-67. PubMed ID: 28895868
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of snake envenomation-induced renal dysfunction in dogs using early urinary biomarkers of nephrotoxicity.
Hrovat A; Schoeman JP; de Laat B; Meyer E; Smets P; Goddard A; Nagel S; Daminet S
Vet J; 2013 Oct; 198(1):239-44. PubMed ID: 23916665
[TBL] [Abstract][Full Text] [Related]
15. Escherichia coli pyometra induces transient glomerular and tubular dysfunction in dogs.
Maddens B; Daminet S; Smets P; Meyer E
J Vet Intern Med; 2010; 24(6):1263-70. PubMed ID: 21039862
[TBL] [Abstract][Full Text] [Related]
16. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
[TBL] [Abstract][Full Text] [Related]
17. Use of urinary γ-glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with leishmaniasis treated with N-methylglucamine antimoniate.
Paltrinieri S; Mangiagalli G; Ibba F
Res Vet Sci; 2018 Aug; 119():52-55. PubMed ID: 29857246
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment.
Martínez-Subiela S; Bernal LJ; Cerón JJ
Am J Vet Res; 2003 Aug; 64(8):1021-6. PubMed ID: 12926596
[TBL] [Abstract][Full Text] [Related]
19. Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis.
Escribano D; Tvarijonaviciute A; Kocaturk M; Cerón JJ; Pardo-Marín L; Torrecillas A; Yilmaz Z; Martínez-Subiela S
Comp Immunol Microbiol Infect Dis; 2016 Dec; 49():82-87. PubMed ID: 27865270
[TBL] [Abstract][Full Text] [Related]
20. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Miró G; Oliva G; Cruz I; Cañavate C; Mortarino M; Vischer C; Bianciardi P
Vet Dermatol; 2009 Oct; 20(5-6):397-404. PubMed ID: 20178476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
